To improve healthcare worldwide by discovering, developing, and commercializing urgently needed therapeutic products to treat serious viral infections.

We focus on the development of oral drugs with novel mechanisms of action to treat major viruses resistant to existing drugs.

We seek to maintain high standards of integrity while pursuing scientific excellence and innovation, with the objective of creating significant value for our shareholders.

Overview

Panacos is a Delaware Corporation founded in 1992. Panacos' scientific and clinical programs originated in anti-infective technologies designed to prevent the spread of infectious disease by blood transfusions. In March of 2005, Panacos merged with V.I. Technologies, Inc. (Vitex), a biotechnology company developing products designed to improve the safety of the world's blood supply. The merger with Panacos immediately expanded the Vitex pipeline into novel, high value therapeutics. The Panacos team that joined Vitex is recognized for fundamental contributions to HIV biology and drug development. The combined company has a strong intellectual property position and the potential to accomplish significant near term milestones to create value from our promising pipeline.

The corporate headquarters for Panacos is in Watertown, Massachusetts. The Company has an R&D facility in Gaithersburg, Maryland, focused on the discovery and development of novel therapeutics for HIV and other serious viral diseases.